VLTO — Veralto Corporation

Sentiment is constructive but not euphoric. As of 2026-08-27, the Q2 2026 adjusted EPS of $1.11 beat by roughly $0.11, management raised FY2026 core growth to 4.0%-4.5% and adjusted EPS to $4.35-$4.43, and the $465 million Cleanwater1 acquisition extends an active M&A streak. Offsetting that, 7 of 13 analysts rate it Hold, the stock is still ~10% below its 52-week high, and RSI is neutral, so the market is treating it as a high-quality company at a fair price rather than a must-own.

Revenue has climbed steadily from $1.255B in Sep 2023 to $1.474B in Jul 2026, with YoY growth accelerating to 7.6% in Q2 2026 after roughly 4%-5% growth through most of 2024 and 2025 (core sales grew 4.2%, so part of the latest jump is M&A). GAAP diluted EPS rose from $0.74 in Q1 2024 to $1.02 in Q1 2026 and $0.98 in Q2 2026, up 10% YoY but slightly down sequentially; the GAAP operating margin dipped to 21.4% in Q2 2026 from 22.8% a year ago, likely due to acquisition amortization/integration, while non-GAAP adjusted EPS rose 19% and management raised guidance. FCF remains strong: Q2 2026 FCF was $328M and LTM FCF is roughly $1.05B, above LTM net income of approximately $0.99B, so the underlying earnings quality is solid.

Fairly valued relative to its own history, not cheap in absolute terms. As of 2026-08-27, Veralto trades at 24.65x TTM earnings versus a 5-year average of 25.44x, 4.21x sales versus a 5-year average of 4.34x, and roughly 22.5x forward EPS. The PEG ratio of 2.34 looks expensive if you only use near-term EPS growth, but the premium is supported by 60% gross margins, 22.7% operating margins, 16.1% ROIC, negative accruals, and a balance sheet with $2.12B cash and only ~$0.56B net debt.

At $98.37 as of 2026-08-27, the market is paying roughly 22.5x forward earnings for a company guiding 4.0%-4.5% core sales growth and mid-single-to-low-double-digit adjusted EPS growth. The stock is not pricing in a dramatic acceleration, but it is also not pricing in a miss. If management delivers the raised guidance and Cleanwater1 integrates well, the natural drift is toward the $105-$110 area; if core growth fades below 4% or M&A integration disappoints, a de-rate toward 20-21x forward earnings would put the stock near $88-$92.

As of 2026-08-27, RSI was 56.7, neither overbought nor oversold. The stock was 0.8% above its 20-day SMA, 5.1% above its 50-day SMA, and 5.3% above its 200-day SMA, so the trend is constructive but extended mildly. Support sits near the $93.50-$97.60 zone (50/200-day SMAs); resistance is the 52-week high of $109.86. The setup favors waiting for a pullback or a confirmed breakout rather than chasing the current price.

• Stringent water-quality and PFAS/contaminant regulations are creating durable, non-discretionary demand for treatment and disinfection technology.
• Municipal water infrastructure spending is generally recession-resistant, but project timing and public budgets can still cause quarterly lumpiness.
• Higher-for-longer interest rates keep valuation multiples under pressure, though Veralto's low net debt and strong FCF allow it to self-fund M&A.
• Tariff and trade policy is a live variable: IEEPA tariff recoveries contributed ~$0.05 to Q2 2026 adjusted EPS, but future tariff costs/recoveries are uncertain.
• Consumer packaging and industrial production trends affect the PQI segment's recurring revenue base, though ~60% recurring revenue provides a cushion.

• Q3 2026 earnings in late October 2026: guidance implies 4.0%-5.0% core sales growth and adjusted EPS of $1.06-$1.09.
• Close and integration of the $465 million Cleanwater1 acquisition, plus early signs of cross-selling in Water Quality.
• Further bolt-on acquisitions in water solutions after In-Situ, GlobalVision, Alfaa UV, and Cleanwater1.
• Renewed PFAS rulemaking or federal/state water infrastructure funding announcements that accelerate demand.
• A shift toward lower interest rates, which could support a higher multiple on a defensive compounder like Veralto.

• M&A integration risk: the 2026 deal streak adds complexity, and debt-to-equity rose to 1.09x even though net debt is modest at ~$0.56B.
• Valuation compression: at 24.7x TTM earnings and a 2.34 PEG, any growth disappointment could trigger a rapid re-rate.
• Tariff/input cost volatility: the $0.05 tariff recovery benefit in Q2 may not repeat, and supply-chain costs could rise.
• PQI segment exposure to consumer packaging and industrial production cycles, which could soften in a broader slowdown.
• Foreign exchange translation and acquisition-related amortization can obscure the underlying earnings trend.

Veralto is a high-quality defensive compounder with excellent margins, negative accruals, strong FCF, and secular water-quality tailwinds. As of 2026-08-27, the stock is fairly valued rather than mispriced: my fair-value estimate is about $105.36, so upside from $98.37 is modest. This is a hold/accumulate-on-dips candidate, not a compelling chase at current levels.

Applied a justified forward P/E of 24.0x to the FY2026 adjusted EPS guidance midpoint of $4.39, a ~1.5-turn discount to the 5-year average P/E of 25.44x to account for the rich PEG and interest-rate risk; this gives $105.36, and cross-checking with LTM FCF of ~$1.05B implies a reasonable ~4.1% FCF yield.